News

January 21, 2019

SmartTarget Improves Prostate Cancer Detection During Biopsies, Study Says

News

SmartTarget, an image fusion software that combines magnetic resonance imaging (MRI) and ultrasounds, should be used along with a visual review of MRI scans to conduct biopsies in patients ... Read more

January 17, 2019

Erleada Approved in Europe for Castration-resistant Prostate Cancer Patients at High Risk of Metastasis

News

The European Commission has approved the use of Erleada (apalutamide) for the treatment of men with castration-resistant prostate cancer at high risk of developing metastasis, announced Janssen Oncology, the therapy’s developer. The ... Read more

January 16, 2019

Coffee and Tea Intake Not Linked to Prostate Cancer Risk, According to Large European Study

News

Drinking tea or coffee, with or without caffeine, has no impact on the risk for prostate cancer, according to the results of a large European study. The study, “Coffee ... Read more

January 14, 2019

Prostate Cancer Scoring Method May Not Accurately Predict Outcomes in Black Men, Study Suggests

News

Black men diagnosed with low-risk prostate cancer are two times more likely to actually have a more aggressive, fatal form of the disease than those of other races, suggesting ... Read more

January 10, 2019

Phase 2 Trial of Tomivosertib Begins Dosing Advanced Castration-resistant PC Patients

News

A Phase 2 clinical trial evaluating eFFECTOR Therapeutics’ investigational therapy tomivosertib (eFT508), for men with advanced castrate-resistant prostate cancer (CRPC) who failed to respond to androgen receptor signaling (ARS) inhibitors, has ... Read more

January 7, 2019

Phase 2 Trial Assessing CPI-1205, Plus Xtandi, Begins Dosing Metastatic CRPC Patients

News

Constellation Pharmaceuticals has begun patient dosing in the second part of a Phase 1b/2 trial testing its investigational inhibitor CPI-1205, in combination with Xtandi (enzalutamide), for the second-line treatment of ... Read more

January 3, 2019

Trial Studies Gold Nanoparticles as Way to Eliminate Localized Prostate Cancer

News

A new approach that uses light-activated gold nanoparticles is being tested in a small clinical trial as a way to eliminate prostate cancer in patients with localized tumors. The ... Read more

January 2, 2019

10-Year Survival of Young Low- and Intermediate-risk Prostate Cancer Patients Better with Radiation than Surgery

News

Radiation therapy approaches — including brachytherapy and external beam radiation therapy (EBRT) — lead to better 10-year survival rates than prostate surgery in young patients with low- and intermediate-risk ... Read more

December 12, 2018

Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient

News

A Phase 3 trial evaluating Progenics Pharmaceuticals‘ new imaging agent to help detect prostate cancer recurrence has begun dosing participants. The agent, called PyL (18F-DCFPyl), is a tracing substance composed of the ... Read more